

02.05.2026

To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra-Kurla Complex,
Bandra (East) Mumbai 400 051

BSE Limited
Floor- 25, P J Tower,
Dalal Street,
Mumbai 400 001

SYMBOL:- EPIGRAL

Scrip Code: 543332

Dear Sirs,

Sub.: Investors Presentation on Audited Financial Results – Q4 & FY2026

Ref.: Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith Investors Presentation on Audited Financial Results – Q4 & FY2026.

The said Earnings Presentation is also available at www.epigral.com in the Investor Relations section.

This is for information and records.

Thanking you,

Yours faithfully,

For Epigral Limited

GAURANG
GHANSHYAM
TRIVEDI

Digitally signed by
GAURANG GHANSHYAM
TRIVEDI
Date: 2026.05.02 16:03:17
+05'30'

Gaurang Trivedi

Company Secretary & Compliance Officer

M. No. 22307



Epigral Limited

Epigral Tower, Behind Safal Profitaire, Corporate Road
Prahladnagar, Ahmedabad 380015, Gujarat, India.

T +91 79 2970 9600

E info@epigral.com

W epigral.com



EPIGRAL



Epigral Limited

Investor Presentation – Q4 and FY2026



Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Epigral Limited (the “Company”) solely for the information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company

Certain statements in this presentation concerning our future growth prospects are forward looking statements which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The Risk and uncertainties relating to the statements include, but are not limited to, risks and uncertainties regarding fiscal policy, competition, inflationary pressures and general economic conditions affecting demand / supply and price conditions in domestic and international markets. The company does not undertake to update any forward -looking statement that may be made from time to time by or on behalf of the company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. The Company does not make any promise to update/provide such presentation along with results to be declared in the coming years.

The logo for EPIGRAL, featuring the word in a bold, sans-serif font. The letter 'I' is stylized with a vertical bar that transitions through colors: orange at the top, yellow in the middle, and red at the bottom.

EPIGRAL

A vertical bar on the left side of the slide, transitioning through colors: orange at the top, yellow in the middle, red in the middle, and purple at the bottom.

Q4 and FY2026 Result update

Key Highlights

Q4FY26 Key Highlights:

- QoQ sales volume grew by 15% and overall plant utilization stood above 80%
- Highest ever revenue of ₹ 736 Crore, a 22% growth, due to volume growth and improved realization
- Revenue contribution from Derivatives & Specialty business increased to 54% in Q4FY26 vs 52% in Q3FY26
- Absolute EBITDA grew by 64% to ₹ 169 Crore vs ₹ 103 Crore in Q3FY26.
- EBITDA margin stood at 23% vs 17% in Q3FY26, on account of improved utilization level and normalized inventory cost
- PAT rose by 109% to ₹ 82 Crore vs ₹ 39 Crore in Q3FY26. PAT margin stood at 11%

FY2026 Key Highlights:

- Revenue dropped by 1% to ₹ 2,542 Crore due to a 4% drop in sales volume
- EBITDA stood at ₹ 567 Crore vs ₹ 711 Crore in FY2025. EBITDA margin stood at 23%.
- PAT stood at ₹ 333 Crore, however PAT without deferred tax liability benefit stood at ₹ 252 Crore
- ROCE stood at 16% in FY2026, compared to 25% in FY2025 due to lower utilization levels, a sizeable capital work in progress and profitability impacted by an increase in RM Prices
- Net Debt/EBITDA stood to 0.9x as on 31st March 2026 vs 0.7x as on 31st March 2025

Key Highlights

FY2026 Strategic Highlights:

- Epigral board proposed final dividend of ₹ 5 per share, 50% on face value of ₹ 10.
- Epigral spent ₹ 394 Crore on capex in FY2026
- Capex plans are moving as per schedule and are expected to get commissioned within the timeline and budget
 - CPVC Resin capacity will reach to 1,50,000 TPA, by adding additional 75,000 TPA
 - Epichlorohydrin capacity will reach to 1,00,000 TPA, by adding additional 50,000 TPA
 - Wind Solar Hybrid Power Plant capacity will reach to 38.14 MW, by adding additional 19.80 MW
- Epigral has been awarded the EcoVadis Silver Medal and Responsible Care has been renewed for another 3 years



CMD Message

“In Q4 FY26, we delivered record revenue of ₹736 crore, driven by a 15% sequential increase and 14% year-on-year growth in volumes. This performance reflects strong demand conditions and a full recovery post scheduled maintenance in Q3. Improved utilization levels and stabilization in raw material costs supported EBITDA margins of 23%.

While FY26 saw some impact due to an extended monsoon and planned maintenance in the first half, demand recovery began in November and strengthened through Q4. We expect this momentum to continue into FY27, subject to global macro conditions.


Our diversified product portfolio continues to provide resilience amid geopolitical uncertainties, including developments in West Asia. At the same time, our ongoing capex projects for Epichlorohydrin and CPVC expansion are progressing as planned and within budget. Once commissioned, these plants will address India’s growing demand and enhance our financial performance.

With these projects nearing completion and a pipeline of new initiatives focused on further integration, we are well-positioned to deliver consistent growth and long-term value for our stakeholders.”


- Mr. Maulik Patel, Chairman and Managing Director

Q4FY26 Financial Highlights


Revenue



EBITDA




PAT




₹ Crore ——— Margin -%

FY2026 Financial Highlights


Revenue



EBIDTA



PAT




₹ Crore ——— Margin -%


*As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 333 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 252 Cr.

Key ratios as on 31st March 2026


ROCE (%)*#



ROE (%)*




Net Debt/EBITDA (x)*



*TTM EBIT, PAT and EBITDA are considered for above ratios

#Capital employed in ROCE includes Capital Work in Progress

Revenue Transition towards Derivatives & Specialty Chemicals



Capex Plan – Enhancing CPVC and Epichlorohydrin capacity

CPVC

Project Details

- Additional capacity – 75,000 TPA
- Total capacity after expansion – 1,50,000 TPA (World's largest plant by capacity)
- Expected commissioning – H1FY27

Rationale

- Demand in India is expected to grow at ~ 12% - 13% CAGR
- Increasing Chlorine consumption in house, further strengthening integrated complex
- For CPVC, Epigral has established itself, for setting up plant, operating plant efficiently and having good market presence

Epichlorohydrin (ECH)

Project Details

- Additional capacity – 50,000 TPA
- Total capacity after expansion – 1,00,000 TPA (India's largest plant by capacity)
- Expected commissioning – H1FY27


Rationale

- Demand in India is expected to grow at high double digit %
- Increasing captive consumption of Chlorine, Hydrogen and Caustic Soda, further strengthening integrated complex
- For ECH, Epigral has established itself, for setting up plant, operating plant efficiently and having good market presence both in India and globally

Capex Project Update as on 31st March 2026

Product	Capacity	Expected Commissioning Date
Chlorotoluenes Value Chain	-	Commissioned March 2025
Wind Solar Hybrid Power Plant (Additional)	19.80 MW	Q2FY27
CPVC Resin (Additional)	75 KTPA	Q2FY27
Epichlorohydrin (Additional)	50 KTPA	Q2FY27

Capex Spends - ₹ Crore



Income Statement

Particulars (₹ Crore)	Quarterly					Annually		
	Q4FY26	Q4FY25	YoY %	Q3FY26	QoQ %	FY2026	FY2025	YoY %
Total Revenue	736	631	17%	603	22%	2,542	2,565	-1%
Gross Profit	272	261	4%	197	39%	941	1,067	-12%
Gross Margin (%)	37%	42%		33%		37%	42%	
EBITDA	169	173	-3%	103	64%	567	711	-20%
EBITDA Margin (%)	23%	28%		17%		22%	28%	
Depreciation	42	34	23%	43	-2%	168	133	27%
Finance Cost	16	12	34%	11	44%	72	53	35%
PBT	111	131	-16%	55	102%	342	540	-37%
PAT	82	87	-5%	39	109%	333*	357	-7%
PAT Margin (%)	11%	14%		6%		13%	14%	
EPS (₹)	19.0	20.1		9.1		77.1	84.4	

*As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 333 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 252 Cr for FY2026.






The logo for EPIGRAL, featuring the word in a bold, sans-serif font. The letter 'I' is stylized with a vertical bar that transitions through colors: orange at the top, yellow in the middle, and red at the bottom.


EPIGRAL

The title 'Company Overview' is displayed in a large, grey, sans-serif font. To the left of the text is a vertical bar with a color gradient from orange at the top to purple at the bottom.

Company Overview

Company Overview

-  **Founded:**
2007
-  **Employees:**
1,100 +
-  **Capacity: Chlor-Alkali# – 421 KTPA**
Derivatives# – 250 KTPA
-  **Certified:**
EcoVadis Silver Medal
-  **Manufacturing facility:**
Fully-integrated & automated complex



Chlor-Alkali : Caustic Soda - 400 KTPA and Caustic Potash - 21 KTPA

Derivatives : CPVC Resin – 75 KTPA, Epichlorohydrin – 50 KTPA, Chlorotoluenes Value Chain – 15 KTPA, Chloromethanes - 50 KTPA and Hydrogen Peroxide - 60 KTPA

Our Journey

FY 2007

Epigral Ltd (MFL)
incorporated

FY 2010

Commissioned 1st
Plant

- **Caustic Soda – 119 KTPA**
- **CPP – 40 MW**

FY 2015

Increased capacity to

- **Caustic Soda – 167 KTPA**
- **CPP – 60 MW**

FY 2017

Commissioned

- **Caustic Potash – 21 KTPA**

Converted all
Membrane to Zero Gap

FY 2020

Commissioned

- **Chloromethanes – 50 KTPA**

FY 2021

Commissioned

- **Hydrogen Peroxide – 60 KTPA**

Increased capacity to

- **Caustic Soda – 294 KTPA**
- **CPP 96 MW**

Awarded “**Responsible Care**” Certificate

FY 2022

Listed as an independent entity
on 18th August 2021

FY 2023

Commissioned

- **Epichlorohydrin – 50 KTPA**
- **CPVC Resin – 30 KTPA**

Increased capacity to

- **Caustic Soda – 400 KTPA**
- **CPP – 132 MW**

FY 2024

Renamed company from
Meghmani Finechem to Epigral

Commissioned

- **18.34 MW Green Hybrid Power Plant**

Inaugurated R&D Centre

FY 2025

Commissioned

- **CPVC Resin – 45 KTPA**
(Total capacity stood at 75 KTPA)
- **CPVC Compound – 35 KTPA**
- **Chlorotoluenes Value Chain**

Announced Capex

- **CPVC Resin – additional 75 KTPA**
- **Epichlorohydrin – additional 50 KTPA**



Our Values



TOGETHER

Teamwork
Passion
Relationships



CARING for

Quality Colleagues
EHS



AGILE

On time
OTIF
Faster



MAKE IT HAPPEN

Keep promises
Own the outcome

Together, in caring and agile manner, we make it happen

Chlor-Alkali

Caustic Soda (NaOH)

❖ Expected demand CAGR: ~ 8%



Alumina



Textile



Chemicals

- We are 4th largest producer in India
- Caustic Soda is basic raw material and caters to many industries. Major industries are alumina, textile, chemical, etc.
- Domestic demand for Caustic Soda is expected to increase to 5.0 million ton by FY2027
- Co-products are key raw material for our value added downstream products (CMS, H₂O₂, ECH and CPVC)

Caustic Potash (KOH)

❖ Expected Demand CAGR: ~ 8%



Agrochemicals



API

- We are 3rd largest producer in India
- Caustic Potash is majorly consumed in soap & detergent, agrochemical and pharmaceutical industry
- The India's capacity stands at 83 KTPA
- Co-products are key raw material for our value added downstream products (CMS, H₂O₂, ECH and CPVC)

Derivative Products

Chloromethanes (CMS)

❖ Expected demand CAGR: ~ 12%



Solvent in Pharma



PTFE Pipes



Refrigerant Gas

- We are 6th largest producer in India
- CMS plant produces 3 products, MDC, Chloroform and CTC. It is majorly drive by MDC
- The India's capacity stands at 677 KPTA
- CMS is used majorly in pharmaceutical, refrigerant, Tetrafluoroethylene (TFE), etc.

Hydrogen Peroxide (H2O2)

❖ Expected demand CAGR: ~ 10%



Paper & pulp



Textile



Chemicals

- We are 5th largest producer in India
- H2O2 demand will continue to grow driven by diverse industrial uses – paper & pulp, textiles, effluent treatment, chemicals, etc.
- The India's capacity stands at 429 KTPA

Derivatives & Specialty Chemicals

CPVC

❖ Expected demand CAGR: ~ 13%



Pipes and Fixtures



- Expanding – Will be world's largest manufacturer
- Key raw material for heat resistant pipes
- Growing demand of CPVC in India for Pipe and Fittings in residential and commercial properties
- Cater to both CPVC Resin and CPVC compound customer
- India is net importer of CPVC

Epichlorohydrin (ECH)

❖ Expected demand CAGR: ~ 15%



Wind mill



Automobile



Adhesives

- 1st company in India to produce sustainable bio based ECH
- Domestic alternative for 100% imported product
- Consuming Chlorine, Hydrogen and Caustic Soda – Strengthening integrated complex
- Catering to epoxy resin, pharmaceutical, water treatment chemicals and various other industries

Derivatives & Specialty Chemicals

Chlorotoluenes Value Chain

❖ Expected demand CAGR: Double digit %



Agrochemicals




API

- 1st company in India to commission this value chain
- Will serve Intermediates for manufacturing pharmaceutical and agrochemical active ingredients
- In 1st phase, ~ 10 to 12 set of products will be manufactured through following reactions – Chlorination, Photo Chlorination, Hydrolysis and Cyanation
- Chlorine will be consumed as raw material – strengthening integrated complex

Diversified and integrated portfolio

Fully Integrated Product Portfolio



High Value Products


Import Substitution – Make in India

Diversified End User Industries

Sole Manufacturer of ECH in India

Diversifying Portfolio; De-Risking Business Model

Fully Integrated Complex



Competitive Strength



Well Invested Infrastructure

- State of the art manufacturing facility
- Strategic location with close connectivity to ports and raw material availability.
- Secured land for future growth of 5 to 7 years



Well established brand

- Epigral is a known brand in Indian chemical market
- Serving domestic customers for last 14 Yrs
- Pan India reach through a wide network of distributors



Focused on Efficiency

- Low cost operations as fully backward and forward integration
- Fully automated complex
- Continuous addition of value added products




Diversified Application Base

- Catering to more than 16 industries
- Revenue split is evened out among customer base
- End user market growing rapidly

Underpinned by a Technically Qualified Leadership Team

Catering to high growth industries

Increased market potential & higher growth exposure



The addressable market for Epigral is growing ~10-13% in the next 5 years

Key Customers



SNF



Westlake
Epoxy




SUMITOMO DEUTSCHLAND GMBH




Diversified Product Portfolio

Manufacturing Plant Capacity (KTPA)




*Expected Commissioning, * Commissioning date*

Transitioning towards Derivatives & Specialty Chemicals



■ Derivatives & Specialty ■ Chlor-Alkali



■ Derivatives & Specialty ■ Chlor-Alkali

Revenue from the derivatives and specialty segment to be ~ 70% by FY28E

Research & Development Centre

- A step towards **strengthening presence in Specialty chemicals**
- **Location Changodar, Ahmedabad**
- R&D center will be used for creating further molecules for Chlorotoluene and other new molecules, which will be intermediates for pharmaceutical and agrochemical active ingredients
- **Our reaction expertise**
 - Electrolysis
 - Hydrogenation
 - Ring Chlorination
 - Hydrolysis
 - Cyanation
 - Chlorination
 - Hydro Chlorination
 - Photo Chlorination
 - Diazotization
 - Oxidation



Focused on ESG

ENVIRONMENT

- Focused on using **best technology** to manage critical resources, to moderate the consumption of energy and natural resources and drive operations efficiently
- Focus is to manufacture more from less, basis for environment responsibility
- **Entered in JV to set up 38.14 MW Wind-Solar Hybrid Power Plant for internal consumption**
- Intend is to minimize effluents discharge while moderating water consumption
- **First company to produce sustainable bio-based Epichlorohydrin**
- **Safety protocols imbibing in the culture** of the company and timely management review safety systems with quantified leading and lagging indicators



SOCIAL RESPONSIBILITY

- **Employees** – Investment in culture of excellence, timely training, scope for growth, talent investment, extensive safety provisions and supporting financially and mentally in difficult times
- **Community** – Engaged community around manufacturing plant. Supporting them in difficult times. Deeply rooted CSR in the area of education, health & family welfare, sustainable livelihood, infrastructure and other social activities
- **Customers and vendors** – Strong and long relation with customers and vendors. Over a period built on ecosystem of vendors and primary customers

GOVERNANCE

- Qualified and experienced board driving strategic decisions, ethics and values
- Focus on managing the business in transparent manner with all stakeholders
- All the strategic decisions are taken considering interest of minority shareholders
- Reputed statutory auditor - SRBC & Co LLP
- Timely disclosure of material announcements



Experienced and qualified board

Mr. Maulik Patel

Chairman & Managing Director

He has 16 years of experience in the chemical industry. He has played a key role in growth of Epigral. He actively looks after operations, projects expansion, identifying new products, building a team, etc. He has done MSc in chemical engineering and MBA.

Mr. Kaushal Soparkar

Executive Director

He has 15 years of experience in the chemical industry. He actively looks after finance, IT and Human Resource. He has done MS in Engineering Management.

Mr. Ankit Patel

Non-Executive, Non-Independent Director

He has 14 years of experience in the chemical industry. He is Chairman & Managing Director at Meghmani Organics Limited. He has done MS in Engineering Management and MBA.

Mr. Karana Patel

Non-Executive, Non-Independent Director

He has 14 years of experience in the chemical industry. He is Executive Director at Meghmani Organics Limited and looks after the Agrochemicals division. He has done diploma and B.E. in chemicals.

Mr. Darshan Patel

Non-Executive, Non-Independent Director

He has 13 years of experience in the chemical industry. He is Executive Director at Meghmani Organics Ltd and looks after the pigment division. He has done MS in Engineering Management and MBA.

Mr. Manu Patel

Non-Executive, Independent Director

He is a Chartered Accountant. He was associated with Zydus Group for 35 years and was heading Finance & Taxation. He has expertise in the field of Forex, Treasury and Credit Management.

Mr. Sanjay Asher

Non-Executive, Independent Director

He is a senior partner with M/s Crawford Bayley & Co and practicing advocate since 1991. He specializes in the field of M&A, JVs, Private Equity and Capital Markets. He is a CA and LLB graduate.

Mr. Kanu Patel

Non-Executive, Independent Director

He is CMD at Voltamp Transformers Ltd and has been associated with the company for more than 41 years. He has expertise in finance, marketing, commercial matters and strategic planning. He is a member of ICAI and ICSI.

Mr. Raju Swamy

Non-Executive, Independent Director

He is into management consulting in family business for over 35 years. He has expertise in marketing, projects and HR. He has done MBA from IIM Calcutta,

Mrs. Priyanka Chopra

Non-Executive, Independent Director

She is CEO at IIMA Ventures. She has expertise in investing, advising and engaging with early stage companies. She holds MBA from The Wharton School and M.S. in Electrical Engineering from the Georgia Institute of Technology.

- **Board comprises of accomplished and knowledgeable directors, contributing diverse expertise and perspective to our collective decision making**
- **50% of the board comprises of Independent Directors**
- **Our 5 board committees are chaired by an Independent Director**

Growth Strategy

Forward & Backward Integration:

- Scale up capacities in existing products
- New value added products in existing value chains
- Improved market position

Opportunities in high growth sectors:

- Explore opportunities in various sectors
- Increase presence & improve market share
- Entering into products which are fully imported

New Value Chains:

- Expand chemistry expertise to enter new value chains (specialty chemicals)
- Addition of new reaction capabilities

Achieving economies of scale:

- Optimising existing complex
- Achieving efficiency operations to become a low cost producer




EPIGRAL




Historical numbers

Financial Performance – P&L



*As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 333 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 252 Cr for FY2026.

Balance Sheet Ratios



#Capital employed in ROCE includes Capital Work in Progress

Historic Income Statement

Particulars (₹ Cr)	FY2022	FY2023	FY2024	FY2025	FY2026
Total Revenue	1,555	2,196	1,936	2,565	2,542
Gross Profit	716	951	763	1,067	941
Gross Margin (%)	46%	43%	40%	42%	37%
EBITDA	509	689	481	711	567
EBITDA Margin (%)	33%	31%	25%	28%	22%
Depreciation	86	109	124	133	168
Finance Cost	44	66	73	53	72
PBT	383	523	291	540	342
PAT	253	353	196	357	333*
PAT Margin (%)	16%	16%	10%	14%	13%
EPS (₹)	60.8	85.0	47.1	84.4	77.1

*As the company shifted to new tax rate of 25.17%, deferred tax liability reduced by Rs. 81 Cr, resulting in PAT of Rs. 333 Cr. If we exclude the reduction of deferred tax liability, PAT would be of Rs. 252 Cr for FY2026.

Balance Sheet

Liabilities (₹ Crore)	FY24	FY25	FY26	Assets (₹ Cr)	FY24	FY25	FY26
Share Capital	42	43	43	Fixed Assets	2,249	2,302	2,568
Reserves & Surplus	1,213	1,860	2,178	Financial Assets	29	28	80
Long-Term Borrowings	492	449	334	Other Non-current Assets	14	46	31
Redeemable Pref. Shares	55	0	0	Inventories	263	388	349
Other Non-current Liabilities	214	306	243	Trade Receivables	179	232	417
Short Term Borrowings	416	136	229	Cash & Bank Balances	7	22	5
Trade Payables	184	186	260	Investments	0	77	0
Other Current Liabilities	179	171	218	Loans & Advances	0	0	0
Short Term Provisions	0	0	0	Other Current Assets	53	56	56
Total	2,794	3,151	3,505	Total	2,794	3,151	3,505

EPIGRAL

Enhance to Exceed

Established in 2007, Epigral Limited is a premier integrated chemical manufacturer in India, operating a highly automated and infrastructure-rich complex at Dahej. As a pioneer in the domestic market, the company commissioned India's first Epichlorohydrin (ECH) plant, established the first Chlorotoluenes Value Chain facility, and maintains the nation's largest CPVC production capacity.

Epigral's core portfolio includes high-demand chemistries such as Caustic Soda, Caustic Potash, Chloromethanes, and Hydrogen Peroxide. The company is accelerating its transition toward specialty chemicals by expanding its CPVC and ECH footprints and leveraging its dedicated R&D centre in Ahmedabad to drive innovation and high-value diversification. Committed to sustainable growth and collaborative excellence, Epigral focuses on delivering high-performance solutions that create long-term value for its stakeholders and the broader industry.

For further information

Please log on to website: www.epigral.com

Epigral Corporate Film: [Video](#)

Corporate Office

Epigral Tower, B/h Safal Profitaire, Corporate Road,
Prahladnagar, Ahmedabad 380015,
Gujarat, India

Manufacturing Site

CH/1 and CH/2, GIDC Industrial Estate, Dahej,
Tal. Vagra, Dist. Bharuch – 392130,
Gujarat, India